血清PSA与PAP检测在前列腺癌诊断中的应用价值

The Clinical Value of Serum PSA and PAP determinations in Prostate Cancer Patients

目的 :探讨血清前列腺特异性抗原 (PSA)及酸性磷酸酶 (PAP)对前列腺癌患者的辅助诊断价值。方法 :采用免疫放射分析法 (IRMA)对 98例前列腺癌患者 ,45例前列腺良性疾患及 40例正常健康人进行血清PSA、PAP测定。结果 :前列腺癌组PSA、PAP水平均显著高于前列腺良性疾患组及正常对照组 (P <0 .0 1)。PSA对前列腺癌的灵敏性为 93.9% ,特异性为 93.3% ;PAP对前列腺癌的灵敏性为 71.4% ,特异性为 91.1%。结论 :血清PSA与PAP检测对前列腺癌的早期诊断有较高的临床价值 ,是临床分期、疗效监测及判断预后的重要参考指标。

Objective To investigate the clinical value of serum PSA and PAP determinations in diagnosis of prostate cancer patients. Methods The serum PSA and PAP levels of 98 prostate cancer patienits、 45 prostate benign disease patients and 40 normal subjects were tested by IRMA. Results The serum PSA and PAP levels of prostate cancer patients were significantly higher than those in prostate benign disease patients and nomal contrals ( P <0.01). The diagnostic sensitivity and specificity of serum PSA for prostate cancer were 93.9% and 93.3% respecrively. The diagnostic sensitivity and specificify of serum PAP for prostate cancer were 71.4% and 91.1% respectively. Conclusion The determination of serum PSA and PAP was of high clinical value for diagnosis of early prostate cancer. It could be used as an important reference patameter for the clinical staging, follow-up of treatment result and prediction of prognosis.